ClearPoint Neuro, Inc.

CLPT Healthcare Medical Devices

ClearPoint Neuro, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $37.0 million, up 17.8% from fiscal 2024. In the quarter to June 2026, revenue grew 18.1%, EPS fell 81.0%, free cash flow fell 173.5% and total debt rose 74.1%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

9.07 0.57 −5.91%
Market cap
$294.1M
P/E
0.0×
Fwd P/E
−11.6×
Dividend yield
—
F-score
4/9
Altman Z
0.44
Beneish M
−1.74
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Piotroski F-Score
3 6 4 4 3 4 3 2 4 4
P/S ratio
1.63 2.77 2.33 5.63 19.63 14.27 9.79 6.94 13.24 10.48
Altman Z-Score
(19.13) (8.85) (18.02) (7.74) 0.54 6.07 3.17 (1.36) 11.08 0.44
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(45.53) (22.07) (44.72) (29.14) (9.58) 0.74 (3.48) (11.26) (13.52) (4.93)
Beneish M-Score
(3.82) (2.84) (2.99) (3.36) (1.86) (2.35) (2.30) (2.91) (3.24) (1.74)
P/Operating CF
(8.43) (11.70) (29.46) (135.41) (104.90) (65.49) (65.64) (142.29) (334.42) (32.07)
P/B ratio
0.00 3.50 11.35 13.77 105.96 4.77 5.45 7.86 16.37 13.82
Price to Tangible BV
0.00 4.12 24.20 15.47 140.86 4.82 5.52 8.00 16.44 58.46
EV/Sales
2.57 2.18 2.66 5.32 19.73 11.56 8.45 6.40 12.92 10.56
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(2.54) (2.68) (4.22) (20.92) (32.42) (14.84) (10.74) (11.17) (45.32) (16.33)
EV/FCF
(2.49) (2.67) (4.16) (19.73) (30.50) (14.16) (10.03) (10.22) (40.44) (15.63)
Quick Ratio
1.39 2.33 2.32 1.77 6.87 11.88 5.92 3.55 2.40 4.87
Current Ratio
2.02 2.90 3.56 2.71 7.96 13.02 7.54 4.87 3.22 5.91
Net Debt/EBITDA
(0.17) 0.75 (0.08) 1.00 (0.25) 3.52 1.78 0.63 1.13 (0.14)
Debt/Assets
60.69% 35.39% 44.30% 17.38% 72.09% 15.00% 17.83% 23.32% 0.00% 50.21%
Debt/Equity
(5.94) 0.84 2.30 0.45 8.95 0.20 0.27 0.47 0.00 1.75
Asset Turnover
0.66 0.69 0.68 1.13 0.62 0.34 0.34 0.49 0.77 0.54
Operating CF/Net income
0.72 0.84 0.75 0.51 1.15 0.88 0.98 0.62 0.47 0.94
Capex/Depreciation
(0.17) (0.05) (0.09) (0.16) (0.33) (0.21) (1.38) (0.69) (0.14) (0.22)
Interest Coverage
(7.12) (7.26) (5.35) (4.81) (4.31) (13.75) (201.63) 58.15 (38.10) (10.12)
ROE
589.65% (282.59%) (167.95%) (181.73%) (194.80%) (56.33%) (38.37%) (76.09%) (81.24%) (95.64%)
ROA
(93.09%) (67.30%) (56.66%) (56.01%) (32.73%) (30.31%) (27.15%) (45.01%) (46.22%) (37.30%)
ROIC
(1,114.66%) (271.78%) (173.49%) (298.16%) (109.26%) (185.09%) (109.86%) (175.75%) (233.37%) (48.45%)
Return on Tangible Assets
(237.66%) (83.19%) (119.33%) (79.17%) (30.03%) (24.98%) (36.36%) (73.31%) (75.61%) (46.05%)
Average Days of Receivables
54.97 46.96 61.25 35.47 53.52 52.33 47.33 48.93 54.80 64.66
Research and Development Expense of Revenue
45.71% 38.13% 31.42% 25.05% 36.53% 56.94% 53.01% 48.88% 39.48% 37.59%
Selling, General and Administrative Expense of Revenue
138.57% 108.45% 106.86% 80.76% 83.05% 93.36% 92.30% 101.65% 84.31% 89.15%
Intangible Assets out of Total Assets
0.13 0.06 0.10 0.04 0.02 0.01 0.01 0.01 0.00 0.22
Share Based Compensation of Revenue
21.74% 23.68% 17.80% 7.12% 8.50% 12.75% 20.08% 25.38% 22.00% 22.13%
Graham Net Nets
(0.22) 0.23 0.02 0.05 (0.01) 0.19 0.16 0.09 0.05 (0.02)
Graham Number
4.43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(93.59%) (42.42%) (35.67%) (8.96%) (2.64%) (5.97%) (8.17%) (13.46%) (4.55%) (6.65%)
Free Cash Flow Yield
(63.21%) (29.47%) (27.36%) (4.79%) (3.30%) (5.72%) (8.61%) (9.01%) (2.41%) (6.45%)
Revenue per Share
2.09 0.95 0.67 0.85 0.81 0.79 0.85 0.97 1.16 1.31
Operating CF per Share
(2.11) (0.77) (0.42) (0.22) (0.49) (0.61) (0.67) (0.56) (0.33) (0.84)
Capex per Share
(0.04) 0.00 (0.01) (0.01) (0.03) (0.01) (0.05) (0.04) (0.01) (0.02)
Free Cash Flow per Share
(2.15) (0.78) (0.43) (0.23) (0.52) (0.62) (0.72) (0.60) (0.34) (0.86)
Cash per Share
1.20 1.20 0.28 0.43 1.27 2.61 1.55 0.94 0.74 1.62
Shareholders Equity per Share
(0.27) 0.75 0.14 0.35 0.15 2.35 1.53 0.86 0.94 0.99
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(0.27) 0.75 0.14 0.35 0.15 2.35 1.53 0.86 0.94 0.99
Free Cash Flow
(5.92) (6.02) (4.69) (3.01) (8.29) (12.86) (17.31) (14.77) (9.22) (24.45)
Working Capital
3.07 8.35 4.79 6.55 22.26 57.14 44.39 28.74 23.01 52.84
Capital Expenditures
(0.10) (0.03) (0.06) (0.16) (0.48) (0.17) (1.15) (1.05) (0.27) (0.52)
Net Current Asset Value
(2.07) 4.68 0.31 3.04 (1.68) 45.10 32.58 14.68 19.56 (6.13)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.02 0.00 0.01 0.01 0.04 0.01 0.06 0.04 0.01 0.01
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
1.77 2.03 1.78 2.19 4.51 1.47 1.03 1.09 0.97 0.89
Cash ROIC
(83.97%) (30.04%) (58.00%) (24.36%) (18.94%) (11.41%) (20.54%) (27.22%) (20.28%) (19.87%)
Accounts Receivable Turnover
5.52 8.13 6.74 9.65 8.64 7.73 8.22 8.15 7.92 6.57
Accounts Payable Turnover
2.35 2.51 3.86 5.37 5.86 14.24 20.09 31.10 14.16 11.00
Inventory Turnover
1.48 1.42 1.10 1.47 1.15 1.27 0.99 1.20 1.66 1.88
Average Days of Payables
213.64 95.62 75.14 89.44 29.52 30.11 14.14 13.87 39.87 32.11
Days of Inventory on Hand
244.24 291.39 315.93 300.00 318.65 348.22 483.70 279.23 204.19 213.67
Average Receivables
1.04 0.91 1.09 1.16 1.49 2.11 2.50 2.94 3.96 5.63
Average Payables
1.12 1.15 0.63 0.73 0.63 0.36 0.35 0.33 0.87 1.30
Average Inventory
1.79 2.04 2.21 2.67 3.24 4.09 7.12 8.61 7.39 7.61
Average Assets
8.67 10.65 10.88 9.89 20.72 47.55 60.54 49.08 40.93 68.47
Average Common Equity
(1.37) 2.54 3.67 3.05 3.48 25.58 42.84 29.03 23.28 26.70

Fold the line items

Columns are period end dates